FDA clears 14-month, chemotherapy-free combination for first-line treatment of chronic lymphocytic leukaemia and small lymphocytic lymphoma, backed by positive Phase III AMPLIFY trial data.
Chronic Lymphocytic Leukaemia | 23/02/2026 | By News Bureau
Kernal Biologics receives USD 48 Million from ARPA-H
The funding received by Kernal Biologics from ARPA-H is to develop lower cost in vivo CAR T-cell therapies for hematological cancers.
Chronic Lymphocytic Leukaemia | 09/10/2025 | By Dineshwori | 154
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy